Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
Weimin Li(Sichuan University), Lillian L. Siu(University Health Network), Jérôme Fayette(Université Claude Bernard Lyon 1), Jessica Whiteley(AstraZeneca (United Kingdom)), Melissa de los Reyes(AstraZeneca (Japan)), Dan P. Zandberg(University of Pittsburgh Medical Center), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Athena Matakidou(AstraZeneca (Sweden)), Rajiv Raja(AstraZeneca (United States)), Magdalena Wrona, Nassim Morsli(Boehringer Ingelheim (France)), Zara Ghazoui(AstraZeneca (Sweden)), Helen Mann(AstraZeneca (United Kingdom)), Craig Barker(AstraZeneca (United Kingdom)), Han Si(AstraZeneca (United States)), Qu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Sophie Wildsmith(AstraZeneca (United Kingdom))
Cited by 7
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856